Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may stimulate the immune system to help fight cancer. The purpose of the study is to assess the safety of the investigational drug and to identify the highest dose that is well-tolerated. The pharmacology of VTX-2337 will also be evaluated.
Advanced Solid Tumors|Lymphoma
DRUG: VTX-2337
Safety and identification of dose-limiting toxicities, Study duration|Pharmacokinetics, First dose of investigational drug
Pharmacodynamics, Study duration|Identification of the MTD, First cycle of investigational drug
This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may stimulate the immune system to help fight cancer. The purpose of the study is to assess the safety of the investigational drug and to identify the highest dose that is well-tolerated. The pharmacology of VTX-2337 will also be evaluated.